Contribution: Industrial Research Assistance Program – Contributions to Firms
Providence Therapeutics Holdings Inc.
$6,400,000.00
COVID-19 VI Providence
EF 2020-21 · 2020-09-01
Résumé
Providence Therapeutics, Canada’s leading mRNA vaccine manufacture, is manufacturing an mRNA vaccine against COVID-19. The company is in the R&D phases to demonstrate the preclinical and clinical efficacy of PTX-COVID19-B.
Ministère
Programme
Industrial Research Assistance Program – Contributions to FirmsIndustrial Research Assistance Program-Contributions to Firms (lien de confiance élevée)
Bénéficiaire
Emplacement
Calgary|Calgary, Alberta, Canada
Type de bénéficiaire
For-profit organization
Numéro d'entreprise
738045079
Type
Contribution
Source
Proactive Disclosure - Grants and Contributions
Modifications
Chaque version de l'entente telle que publiée, de la plus ancienne à la plus récente, avec son total à cette version. Le montant ci-dessus est le plus récent.
| Modification | Date | Exercice financier | Total |
|---|---|---|---|
| 1 | 2020-09-01 | 2020-21 | $4,700,000.00 |
| 5 | 2020-09-01 | 2020-21 | $6,400,000.00 |
| 6 | 2020-09-01 | 2020-21 | $6,400,000.00 |
Tel que publié
Additional Information
This agreement has been amended 1 time(s). The end date of this agreements has been modified by 30 days.
Additional Information (French)
Cet accord a été modifié 1 fois La date de fin du présent accord a été changé de 30 jours.
Agreement End Date
2021-07-30
Agreement Number
957288
Agreement Start Date
2020-09-01
Agreement Title
COVID-19 VI Providence
Agreement Title (French)
COVID-19 - Providence VI
Agreement Type
Contribution
Agreement Value
$6,400,000.00
Amendment Date
2021-07-05
Amendment Number
6
Coverage
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation. | Les projets des Contributions aux entreprises stimulent la création de richesse au Canada grâce à l’innovation technologique.
Description
Providence Therapeutics, Canada’s leading mRNA vaccine manufacture, is manufacturing an mRNA vaccine against COVID-19. The company is in the R&D phases to demonstrate the preclinical and clinical efficacy of PTX-COVID19-B.
Description (French)
Providence Therapeutics, le principal fabricant canadien de vaccins à ARNm du Canada, fabrique un vaccin à ARNm contre la COVID-19. L'entreprise est en phase de R-D pour démontrer l'efficacité préclinique et clinique du PTX-COVID19-B.
Expected Results
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Expected Results (French)
Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation
Federal Riding
Calgary Shepard
Federal Riding (French)
Calgary Shepard
Federal Riding Number
48011
NAICS Code
3254
Organization Code
nrc-cnrc
Organization
National Research Council Canada | Conseil national de recherches Canada
Program Name
Industrial Research Assistance Program – Contributions to Firms
Program Name (French)
Programme d’aide à la recherche industrielle – Contributions aux entreprises
Program Purpose
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Program Purpose (French)
Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation
Recipient Business Number
738045079
Recipient City
Calgary|Calgary
Recipient Country
CA
Recipient Legal Name
Providence Therapeutics Holdings Inc.
Recipient Postal Code
T2Z 3P4
Recipient Province or Territory
AB
Recipient Type
F
Reference Number
172-2020-2021-Q3-957288
